Authors
- Somayyeh Zarrati
- Sobhan Fayezi
- Hamid Sadighiyan
- AbbasAli Imani Foladi
- Mehdi Mahdavi
- Reza Falak
- Narges Tehrani
- Fatemeh Tabatabaee
Abstract
Background: Leishmaniasis is a major infectious disease caused by protozoan parasites of the genusLeishmania.Despite of many efforts have been madeno effective vaccineagainst Leishmania infectionhas been approved yet.The major advantage of DNAvaccine isto induce the expression of antigens, which are unaltered in their protein structure and antigenicity. In this study, in order to increase immunity, thecandidate DNA vaccine has been supplemented with nano-adjuvant and its immunogenicity was tested on BALB/c rats.
Materials and Methods: Considering other studies that have demonstratedLeishmania TSA protein is antigenic in both murine and human systems, in this study a new nanovaccinecontaining TSA recombinant plasmid and poly(methylmethacrylate) (PMMA) nanoparticles (as an adjuvant) was designed. After three intramuscular injection of nanovaccine (100 µg),the recombinant TSA protein(20 µg) was injected subcutaneously.3 weeks later,animal were infected by Leishmania major.Finally lymphocyte proliferation and cellular immune responses (IFN-γ,IL-4 prodution) were evaluated byusinigBrdu and ELISA methods.
Results: Theresultsof this study showed that the new nanovaccine was capable of inducing both cytokines secretion,but predominant Th1 immune response characterized by IFN-γ production compared to control groups.
Conclusion: Results revealed that, current candidate nanovaccine has potency for future studies to prepare vaccine against Leishmania.
Keywords
)